Molecular Partners Ag (MOLN) Shares Outstanding (2020 - 2026)
Molecular Partners Ag's (MOLN) quarterly Shares Outstanding (Entity) came in at $40.4 million in Q4 2025, little changed year-over-year from $40.4 million in Q4 2024, and little changed quarter-over-quarter from $40.4 million in Q4 2024.
Analysis
Molecular Partners Ag (MOLN) Shares Outstanding (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Shares Outstanding (Entity) for 6 consecutive years, with $40.4 million the latest figure, recorded in Q4 2025.
- On a quarterly basis, Shares Outstanding (Entity) changed 0.03% year-over-year to $40.4 million in Q4 2025; TTM through Dec 2025 was $40.4 million, a 0.03% change from a year earlier, with the FY2025 full-year figure at $40.4 million, changed 0.03% from the prior year.
- Shares Outstanding (Entity) was $40.4 million for Q4 2025 at Molecular Partners Ag, roughly flat from $40.4 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $40.4 million in Q4 2025 and troughed at $32.3 million in Q4 2021.
- A 5-year average of $37.1 million and a median of $36.4 million in 2023 frame the typical range for Shares Outstanding (Entity).
- Across the five-year window, Shares Outstanding (Entity) rose 11.62% in 2022 and gained 0.03% in 2025, its largest moves.
- Over 5 years, Shares Outstanding (Entity) stood at $32.3 million in 2021, then gained by 11.62% to $36.0 million in 2022, then rose by 0.86% to $36.4 million in 2023, then grew by 11.03% to $40.4 million in 2024, then gained by 0.03% to $40.4 million in 2025.
- The last three Shares Outstanding (Entity) figures came in at $40.4 million (Q4 2025), $40.4 million (Q4 2024), and $36.4 million (Q4 2023), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 540.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 1.24 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 253.70 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 102.80 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 61.30 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 398.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 133.61 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 147.70 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 720.78 Mn |
| 10 | Molecular Partners Ag | 156.54 Mn | 156.54 Mn | - | 37.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 37.27 Mn |
| Mar 31, 2026 | 37.27 Mn |
| Dec 31, 2025 | 37.27 Mn |
| Sep 30, 2025 | 34.03 Mn |
| Jun 30, 2025 | 34.03 Mn |
| Mar 31, 2025 | 34.03 Mn |
| Dec 31, 2024 | 34.03 Mn |
| Sep 30, 2024 | 32.77 Mn |
| Jun 30, 2024 | 32.77 Mn |
| Mar 31, 2024 | 32.77 Mn |
| Dec 31, 2023 | 32.77 Mn |
| Sep 30, 2023 | 32.47 Mn |
| Jun 30, 2023 | 32.47 Mn |
| Mar 31, 2023 | 32.47 Mn |
| Dec 31, 2022 | 32.47 Mn |
| Sep 30, 2022 | 31.01 Mn |
| Jun 30, 2022 | 31.01 Mn |
| Mar 31, 2022 | 31.01 Mn |
| Dec 31, 2021 | 31.01 Mn |
| Sep 30, 2021 | 25.00 Mn |